5A
Apolipoprotein A-I mimetic peptide 5A
37 Amino Acids · MW: ~4100 Da
Amino Acids
37
Molecular Weight
~4100 Da
Half-life
Hours to days depending on formulation
Research Score
4.1
Studies
41
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is 5A?
5A is a bihelical apoA-I mimetic peptide developed to improve cholesterol handling and HDL functionality. It has been studied for anti-inflammatory and anti-atherogenic effects in lipid metabolism models.
Key Benefits & Mechanisms
promotes cholesterol efflux
improves HDL function
reduces vascular inflammation
may stabilize plaques
Research Summary
5A has been investigated as a smaller, engineered HDL-mimetic that can modulate lipid handling without being a full apolipoprotein. Preclinical literature supports effects on reverse cholesterol transport and inflammation-related atherosclerosis endpoints.
Related Peptides
Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
CardiovascularNesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
Cardiovascular